Jan 12, 2021
Consistent benefit regardless of CKD etiology
Once, in the not-too-distant past, one could not scan the latest issue of any top-tier medical journal without finding at least one trial extolling the benefits of statin therapy, which lead many to suggest — and not always facetiously — that it was time to add statins to the water.
Since late summer 2019 when the results of DAPA-HF were reported at the 2019 European Society of Cardiology Congress in Paris, SGLT2 inhibitors have displaced statins as the pharmaceutical of choice for those who like the “one-drug-fits-all-conditions” approach to the art of medicine.
The latest entry comes from David C. Wheeler, MB, ChB, MD of the George Institute for Global Health in Sydney, Australia, who with his co-investigators offers another look at the findings from DAPA-CKD in